{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:52:41Z","timestamp":1649119961078},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,10,19]],"date-time":"2016-10-19T00:00:00Z","timestamp":1476835200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00120-016-0249-4","type":"journal-article","created":{"date-parts":[[2016,10,19]],"date-time":"2016-10-19T06:14:24Z","timestamp":1476857664000},"page":"1419-1432","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Minimal-invasive Therapie des benignen Prostatasyndroms"],"prefix":"10.1007","volume":"55","author":[{"given":"G.","family":"Magistro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gratzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,19]]},"reference":[{"issue":"Suppl 1","key":"249_CR1","first-page":"1","volume":"22","author":"C Vuichoud","year":"2015","unstructured":"Vuichoud C, Loughlin KR (2015) Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol 22(Suppl 1):1\u20136","journal-title":"Can J Urol"},{"issue":"4","key":"249_CR2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s11934-996-0006-0","volume":"7","author":"DA Taub","year":"2006","unstructured":"Taub DA, Wei JT (2006) The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Curr Urol Rep 7(4):272\u2013281","journal-title":"Curr Urol Rep"},{"issue":"4","key":"249_CR3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.eururo.2007.08.042","volume":"53","author":"JL Bosch","year":"2008","unstructured":"Bosch JL, Bangma CH, Groeneveld FP, Bohnen AM (2008) The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. Eur Urol 53(4):819\u2013825 (discussion 25\u20137)","journal-title":"Eur. Urol."},{"issue":"5","key":"249_CR4","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.01.026","volume":"183","author":"JK Parsons","year":"2010","unstructured":"Parsons JK, Wilt TJ, Wang PY, Barrett-Connor E, Bauer DC, Marshall LM et al (2010) Progression of lower urinary tract symptoms in older men: a community based study. J Urol 183(5):1915\u20131920","journal-title":"J. Urol."},{"issue":"Suppl 3","key":"249_CR5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1464-410X.2008.07497.x","volume":"101","author":"CG Roehrborn","year":"2008","unstructured":"Roehrborn CG (2008) BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 101(Suppl 3):17\u201321","journal-title":"BJU Int."},{"issue":"Suppl 3","key":"249_CR6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000052345","volume":"36","author":"RR Berges","year":"1999","unstructured":"Berges RR, Pientka L (1999) Management of the BPH syndrome in Germany: Who is treated and how? Eur Urol 36(Suppl 3):21\u201327","journal-title":"Eur Urol"},{"issue":"4","key":"249_CR7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000012786","volume":"43","author":"H Boeing","year":"1999","unstructured":"Boeing H, Wahrendorf J, Becker N (1999) EPIC-German y \u2013 a source for studies into diet and risk of chronic diseases. European investigation into cancer and nutrition. Ann Nutr Metab 43(4):195\u2013204","journal-title":"Ann Nutr Metab"},{"issue":"Suppl 1","key":"249_CR8","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/ije\/26.suppl_1.S6","volume":"26","author":"E Riboli","year":"1997","unstructured":"Riboli E, Kaaks R (1997) The EPIC Project: rationale and study design. European prospective investigation into cancer and nutrition. Int J Epidemiol 26(Suppl 1):S6\u2013S14","journal-title":"Int J Epidemiol"},{"key":"249_CR9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.urology.2016.06.021","volume":"95","author":"S Rohrmann","year":"2016","unstructured":"Rohrmann S, Katzke V, Kaaks R (2016) Prevalence and progression of lower urinary tract symptoms in an aging population. Urology 95:158\u2013163. doi: 10.1016\/j.urology.2016.06.021","journal-title":"Urology"},{"issue":"6","key":"249_CR10","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.eururo.2014.01.019","volume":"65","author":"A Agarwal","year":"2014","unstructured":"Agarwal A, Eryuzlu LN, Cartwright R, Thorlund K, Tammela TL, Guyatt GH et al (2014) What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol 65(6):1211\u20131217","journal-title":"Eur. Urol."},{"key":"249_CR11","unstructured":"AWMF (2014) Reg.-Nr:043-035: S2e Leitlinie \u2013 Therapie des Benignen Prostatasyndroms (BPS)"},{"key":"249_CR12","volume-title":"Guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO)","author":"S Gravas","year":"2015","unstructured":"Gravas S et al (2015) Guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). https:\/\/uroweb.org\/wp-content\/uploads\/EAU-Guidelines-Non-Neurogenic-Male-LUTS-Guidelines-2015-v2.pdf Zugegriffen: 06.08.2016"},{"key":"249_CR13","unstructured":"Roehrborn CG et al (2003) American Urological Association guideline: management of benign prostatic hyperplasia (BPH). American Urological Association, Linthicum"},{"key":"249_CR14","volume-title":"American Urological Association guideline: management of benign prostatic hyperplasia (BPH)","author":"KT McVary","year":"2010","unstructured":"McVary KT, Avins AL, Bruskewitz RC (2010) American Urological Association guideline: management of benign prostatic hyperplasia (BPH). American Urological Association, Linthicum"},{"issue":"5","key":"249_CR15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0090-4295(94)80208-4","volume":"44","author":"GL Lu-Yao","year":"1994","unstructured":"Lu-Yao GL, Barry MJ, Chang CH, Wasson JH, Wennberg JE (1994) Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT). Urology 44(5):692\u2013698 (discussion 8\u20139)","journal-title":"Urology"},{"issue":"2 Pt 1","key":"249_CR16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0022-5347(17)32762-3","volume":"152","author":"JD McConnell","year":"1994","unstructured":"McConnell JD (1994) Benign prostatic hyperplasia. J\u00a0Urol 152(2 Pt 1):459\u2013460","journal-title":"J Urol"},{"issue":"3","key":"249_CR17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4103\/0970-1591.42613","volume":"24","author":"AM Saemi","year":"2008","unstructured":"Saemi AM, Folsom JB, Plante MK (2008) Injection therapy for prostatic disease: a renaissance concept. Indian J Urol 24(3):329\u2013335","journal-title":"Indian J Urol"},{"issue":"4","key":"249_CR18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eururo.2004.06.001","volume":"46","author":"P Grise","year":"2004","unstructured":"Grise P, Plante M, Palmer J, Martinez-Sagarra J, Hernandez C, Schettini M et al (2004) Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation. Eur Urol 46(4):496\u2013501 (discussion 502)","journal-title":"Eur. Urol."},{"issue":"1","key":"249_CR19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/01.ju.0000121690.37499.1c","volume":"172","author":"MK Plante","year":"2004","unstructured":"Plante MK, Folsom JB, Zvara P (2004) Prostatic tissue ablation by injection: a literature review. J\u00a0Urol 172(1):20\u201326","journal-title":"J. Urol."},{"issue":"2","key":"249_CR20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/00365599.2012.752404","volume":"47","author":"KE Andersson","year":"2013","unstructured":"Andersson KE (2013) Treatment of lower urinary tract symptoms: agents for intraprostatic injection. Scand J Urol 47(2):83\u201390","journal-title":"Scand J Urol"},{"issue":"8","key":"249_CR21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nrurol.2015.169","volume":"12","author":"G Magistro","year":"2015","unstructured":"Magistro G, Stief CG, Gratzke C (2015) New intraprostatic injectables and prostatic urethral lift for male LUTS. Nat Rev Urol 12(8):461\u2013471","journal-title":"Nat Rev Urol"},{"issue":"5","key":"249_CR22","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.urology.2004.06.073","volume":"64","author":"CP Smith","year":"2004","unstructured":"Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB (2004) Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology 64(5):871\u2013875 (discussion 5)","journal-title":"Urology"},{"issue":"5","key":"249_CR23","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neuro.2005.01.017","volume":"26","author":"KR Aoki","year":"2005","unstructured":"Aoki KR (2005) Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26(5):785\u2013793","journal-title":"Neurotoxicology"},{"issue":"6 Pt 1","key":"249_CR24","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.juro.2006.07.127","volume":"176","author":"YC Chuang","year":"2006","unstructured":"Chuang YC, Chancellor MB (2006) The application of botulinum toxin in the prostate. J\u00a0Urol 176(6 Pt 1):2375\u20132382","journal-title":"J Urol"},{"issue":"4 Pt 1","key":"249_CR25","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/01.ju.0000137844.77524.97","volume":"172","author":"YC Chuang","year":"2004","unstructured":"Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB (2004) Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J\u00a0Urol 172(4 Pt 1):1529\u20131532","journal-title":"J Urol"},{"issue":"20","key":"249_CR26","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1073\/pnas.85.20.7820","volume":"85","author":"S Biasi De","year":"1988","unstructured":"De Biasi S, Rustioni A (1988) Glutamate and substance P coexist in primary afferent terminals in the superficial laminae of spinal cord. Proc Natl Acad Sci USA 85(20):7820\u20137824","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"249_CR27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/0165-6147(94)90147-3","volume":"15","author":"A Dray","year":"1994","unstructured":"Dray A, Urban L, Dickenson A (1994) Pharmacology of chronic pain. Trends Pharmacol Sci 15(6):190\u2013197","journal-title":"Trends Pharmacol Sci"},{"issue":"38","key":"249_CR28","doi-asserted-by":"crossref","first-page":"34846","DOI":"10.1074\/jbc.M202902200","volume":"277","author":"MJ Duggan","year":"2002","unstructured":"Duggan MJ, Quinn CP, Chaddock JA, Purkiss JR, Alexander FC, Doward S et\u00a0al (2002) Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J\u00a0Biol Chem 277(38):34846\u201334852","journal-title":"J Biol Chem"},{"issue":"4","key":"249_CR29","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/0306-4522(82)90056-2","volume":"7","author":"I MacKenzie","year":"1982","unstructured":"MacKenzie I, Burnstock G, Dolly JO (1982) The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 7(4):997\u20131006","journal-title":"Neuroscience"},{"issue":"3 Pt 1","key":"249_CR30","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0022-5347(05)00322-8","volume":"175","author":"DE Rapp","year":"2006","unstructured":"Rapp DE, Turk KW, Bales GT, Cook SP (2006) Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 175(3 Pt 1):1138\u20131142","journal-title":"J Urol"},{"issue":"6 Pt 1","key":"249_CR31","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1097\/01.ju.0000127725.48479.89","volume":"171","author":"CP Smith","year":"2004","unstructured":"Smith CP, Chancellor MB (2004) Emerging role of botulinum toxin in the management of voiding dysfunction. J\u00a0Urol 171(6 Pt 1):2128\u20132137","journal-title":"J Urol"},{"issue":"5","key":"249_CR32","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1097\/01.ju.0000049202.56189.54","volume":"169","author":"CP Smith","year":"2003","unstructured":"Smith CP, Franks ME, McNeil BK, Ghosh R, de Groat WC, Chancellor MB et\u00a0al (2003) Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J\u00a0Urol 169(5):1896\u20131900","journal-title":"J. Urol."},{"key":"249_CR33","doi-asserted-by":"crossref","first-page":"463574","DOI":"10.1100\/2012\/463574","volume":"2012","author":"R Arnouk","year":"2012","unstructured":"Arnouk R, Suzuki Bellucci CH, Benatuil Stull R, de Bessa J Jr., Malave CA, Mendes Gomes C (2012) Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses. ScientificWorldJournal 2012:463574","journal-title":"ScientificWorldJournal"},{"issue":"5","key":"249_CR34","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/j.1464-410X.2006.06479.x","volume":"98","author":"YC Chuang","year":"2006","unstructured":"Chuang YC, Chiang PH, Yoshimura N, De Miguel F, Chancellor MB (2006) Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 98(5):1033\u20131037 (discussion 337)","journal-title":"BJU Int"},{"issue":"3","key":"249_CR35","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.juro.2011.04.062","volume":"186","author":"ED Crawford","year":"2011","unstructured":"Crawford ED, Hirst K, Kusek JW, Donnell RF, Kaplan SA, McVary KT et\u00a0al (2011) Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J\u00a0Urol 186(3):965\u2013970","journal-title":"J. Urol."},{"issue":"1","key":"249_CR36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00345-012-0851-z","volume":"31","author":"A Hamidi Madani","year":"2013","unstructured":"Hamidi Madani A, Enshaei A, Heidarzadeh A, Mokhtari G, Farzan A, Mohiti Asli M et al (2013) Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates. World J Urol 31(1):235\u2013239","journal-title":"World J Urol"},{"issue":"3","key":"249_CR37","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/00365590902811537","volume":"43","author":"HC Kuo","year":"2009","unstructured":"Kuo HC, Liu HT (2009) Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scand J Urol Nephrol 43(3):206\u2013211","journal-title":"Scand J Urol Nephrol"},{"issue":"5","key":"249_CR38","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3349\/ymj.2006.47.5.706","volume":"47","author":"DS Park","year":"2006","unstructured":"Park DS, Cho TW, Lee YK, Lee YT, Hong YK, Jang WK (2006) Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. Yonsei Med J 47(5):706\u2013714","journal-title":"Yonsei Med J"},{"issue":"1","key":"249_CR39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2008.08.475","volume":"73","author":"G Brisinda","year":"2009","unstructured":"Brisinda G, Cadeddu F, Vanella S, Mazzeo P, Marniga G, Maria G (2009) Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology 73(1):90\u201394","journal-title":"Urology"},{"issue":"4","key":"249_CR40","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.urology.2005.04.029","volume":"66","author":"YC Chuang","year":"2005","unstructured":"Chuang YC, Chiang PH, Huang CC, Yoshimura N, Chancellor MB (2005) Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 66(4):775\u2013779","journal-title":"Urology"},{"issue":"4","key":"249_CR41","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.urology.2012.06.004","volume":"80","author":"LM Kort de","year":"2012","unstructured":"de Kort LM, Kok ET, Jonges TN, Rosier PF, Bosch JL (2012) Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia. Urology 80(4):889\u2013893","journal-title":"Urology"},{"issue":"4","key":"249_CR42","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.urology.2004.10.077","volume":"65","author":"HC Kuo","year":"2005","unstructured":"Kuo HC (2005) Prostate botulinum A toxin injection \u2013 an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 65(4):670\u2013674","journal-title":"Urology"},{"issue":"3","key":"249_CR43","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/00365591003649201","volume":"44","author":"M Nikoobakht","year":"2010","unstructured":"Nikoobakht M, Daneshpajooh A, Ahmadi H, Namdari F, Rezaeidanesh M, Amini S et\u00a0al (2010) Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: Initial experience with Dysport. Scand J Urol Nephrol 44(3):151\u2013157","journal-title":"Scand J Urol Nephrol"},{"issue":"11 Pt C","key":"249_CR44","doi-asserted-by":"crossref","first-page":"E837","DOI":"10.1111\/j.1464-410X.2012.11288.x","volume":"110","author":"E Sacco","year":"2012","unstructured":"Sacco E, Bientinesi R, Marangi F, Totaro A, D\u2019Addessi A, Racioppi M et al (2012) Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3\u2011month results of a prospective single-armed cohort study. BJU Int 110(11 Pt C):E837\u2013E344","journal-title":"BJU Int"},{"key":"249_CR45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2490-9-9","volume":"9","author":"J Silva","year":"2009","unstructured":"Silva J, Pinto R, Carvalho T, Botelho F, Silva P, Oliveira R et\u00a0al (2009) Intraprostatic Botulinum toxin type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. BMC Urol 9:9","journal-title":"BMC Urol"},{"issue":"12","key":"249_CR46","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1111\/j.1464-410X.2010.09841.x","volume":"107","author":"J Silva","year":"2011","unstructured":"Silva J, Pinto R, Carvalho T, Botelho F, Silva P, Silva C et\u00a0al (2011) Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. BJU Int 107(12):1950\u20131954","journal-title":"BJU Int"},{"issue":"1","key":"249_CR47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.eururo.2007.08.050","volume":"53","author":"J Silva","year":"2008","unstructured":"Silva J, Silva C, Saraiva L, Silva A, Pinto R, Dinis P et\u00a0al (2008) Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol 53(1):153\u2013159","journal-title":"Eur. Urol."},{"issue":"4","key":"249_CR48","first-page":"291","volume":"66","author":"T Yokoyama","year":"2012","unstructured":"Yokoyama T, Yamamoto Y, Suzuki T, Oguma K, Nagai A (2012) Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia: preliminary results with a newly purified neurotoxin. Acta Med Okayama 66(4):291\u2013297","journal-title":"Acta Med Okayama"},{"issue":"3","key":"249_CR49","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eururo.2012.10.005","volume":"63","author":"M Marberger","year":"2013","unstructured":"Marberger M, Chartier-Kastler E, Egerdie B, Lee KS, Grosse J, Bugarin D et al (2013) A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol 63(3):496\u2013503","journal-title":"Eur. Urol."},{"issue":"2","key":"249_CR50","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0090-4295(03)00477-1","volume":"62","author":"G Maria","year":"2003","unstructured":"Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A (2003) Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 62(2):259\u2013264 (discussion 64\u201365)","journal-title":"Urology"},{"issue":"1","key":"249_CR51","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.juro.2014.02.004","volume":"192","author":"KT McVary","year":"2014","unstructured":"McVary KT, Roehrborn CG, Chartier-Kastler E, Efros M, Bugarin D, Chen R et al (2014) A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200\u202fU to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 192(1):150\u2013156","journal-title":"J. Urol."},{"issue":"1","key":"249_CR52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/MOU.0b013e3283410117","volume":"21","author":"E Chartier-Kastler","year":"2011","unstructured":"Chartier-Kastler E, Mehnert U, Denys P, Giuliano F (2011) Botulinum neurotoxin A for male lower urinary tract symptoms. Curr Opin Urol 21(1):13\u201321","journal-title":"Curr Opin Urol"},{"issue":"4","key":"249_CR53","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","volume":"60","author":"A Mangera","year":"2011","unstructured":"Mangera A, Andersson KE, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A et\u00a0al (2011) Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 60(4):784\u2013795","journal-title":"Eur. Urol."},{"issue":"5","key":"249_CR54","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2013.10.033","volume":"65","author":"A Mangera","year":"2014","unstructured":"Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C et\u00a0al (2014) An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol 65(5):981\u2013990","journal-title":"Eur. Urol."},{"issue":"1","key":"249_CR55","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MOU.0b013e328333ac01","volume":"20","author":"A Oeconomou","year":"2010","unstructured":"Oeconomou A, Madersbacher H (2010) Botulinum neurotoxin A for benign prostatic hyperplasia. Curr Opin Urol 20(1):28\u201336","journal-title":"Curr Opin Urol"},{"issue":"4","key":"249_CR56","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.eururo.2008.06.016","volume":"54","author":"A Oeconomou","year":"2008","unstructured":"Oeconomou A, Madersbacher H, Kiss G, Berger TJ, Melekos M, Rehder P (2008) Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. Eur Urol 54(4):765\u2013775","journal-title":"Eur. Urol."},{"issue":"2","key":"249_CR57","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1517\/13543780903555196","volume":"19","author":"N Shore","year":"2010","unstructured":"Shore N (2010) NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 19(2):305\u2013310","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"249_CR58","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/2040622311423128","volume":"2","author":"N Shore","year":"2011","unstructured":"Shore N, Cowan B (2011) The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. Ther Adv Chronic Dis 2(6):377\u2013383","journal-title":"Ther Adv Chronic Dis"},{"issue":"1\u20133","key":"249_CR59","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1574-6968.1992.tb05881.x","volume":"5","author":"JT Buckley","year":"1992","unstructured":"Buckley JT (1992) The channel-forming toxin aerolysin. FEMS Microbiol Immunol 5(1\u20133):13\u201317","journal-title":"FEMS Microbiol Immunol"},{"issue":"3","key":"249_CR60","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1432-1033.1990.tb19466.x","volume":"194","author":"A Christensson","year":"1990","unstructured":"Christensson A, Laurell CB, Lilja H (1990) Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194(3):755\u2013763","journal-title":"Eur J Biochem"},{"issue":"1","key":"249_CR61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000089731","volume":"76","author":"M Froehner","year":"2006","unstructured":"Froehner M, Hakenberg OW, Koch R, Schmidt U, Meye A, Wirth MP (2006) Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer. Urol Int 76(1):27\u201330","journal-title":"Urol. Int."},{"issue":"1","key":"249_CR62","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/pros.20254","volume":"65","author":"C Savblom","year":"2005","unstructured":"Savblom C, Malm J, Giwercman A, Nilsson JA, Berglund G, Lilja H (2005) Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age. Prostate 65(1):66\u201372","journal-title":"Prostate"},{"issue":"7","key":"249_CR63","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/CAD.0b013e3280bad82d","volume":"18","author":"R Singh","year":"2007","unstructured":"Singh R, Browning JL, Abi-Habib R, Wong K, Williams SA, Merchant R et al (2007) Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. Anticancer Drugs 18(7):809\u2013816","journal-title":"Anticancer Drugs"},{"issue":"5","key":"249_CR64","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jnci\/djk065","volume":"99","author":"SA Williams","year":"2007","unstructured":"Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR (2007) A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 99(5):376\u2013385","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"249_CR65","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.eururo.2010.11.024","volume":"59","author":"SR Denmeade","year":"2011","unstructured":"Denmeade SR, Egerdie B, Steinhoff G, Merchant R, Abi-Habib R, Pommerville P (2011) Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 59(5):747\u2013754","journal-title":"Eur. Urol."},{"key":"249_CR66","unstructured":"Gravas SBA, Descazeaud A, Drake M, Gratzke C, Madersbacher S et al (2015) EAU guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO)"},{"issue":"1","key":"249_CR67","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1464-410X.2011.10342.x","volume":"108","author":"HH Woo","year":"2011","unstructured":"Woo HH, Chin PT, McNicholas TA, Gill HS, Plante MK, Bruskewitz RC et\u00a0al (2011) Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 108(1):82\u201388","journal-title":"BJU Int"},{"issue":"6","key":"249_CR68","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.juro.2013.05.116","volume":"190","author":"CG Roehrborn","year":"2013","unstructured":"Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE et\u00a0al (2013) The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J\u00a0Urol 190(6):2161\u20132167","journal-title":"J. Urol."},{"issue":"1","key":"249_CR69","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/jsm.12333","volume":"11","author":"KT McVary","year":"2014","unstructured":"McVary KT, Gange SN, Shore ND, Bolton DM, Cowan BE, Brown BT et\u00a0al (2014) Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. J\u00a0Sex Med 11(1):279\u2013287","journal-title":"J Sex Med"},{"issue":"3","key":"249_CR70","first-page":"7772","volume":"22","author":"CG Roehrborn","year":"2015","unstructured":"Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL et\u00a0al (2015) Three year results of the prostatic urethral L.I.F.T. study. Can J Urol 22(3):7772\u20137782","journal-title":"Can J Urol"},{"issue":"4","key":"249_CR71","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.eururo.2015.04.024","volume":"68","author":"J Sonksen","year":"2015","unstructured":"Sonksen J, Barber NJ, Speakman MJ, Berges R, Wetterauer U, Greene D et al (2015) Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol 68(4):643\u2013652","journal-title":"Eur. Urol."},{"issue":"4","key":"249_CR72","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bju.12540","volume":"113","author":"AL Cantwell","year":"2014","unstructured":"Cantwell AL, Bogache WK, Richardson SF, Tutrone RF, Barkin J, Fagelson JE et\u00a0al (2014) Multicentre prospective crossover study of the \u201eprostatic urethral lift\u201c for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int 113(4):615\u2013622","journal-title":"BJU Int."},{"issue":"1","key":"249_CR73","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.urology.2011.10.021","volume":"79","author":"PT Chin","year":"2012","unstructured":"Chin PT, Bolton DM, Jack G, Rashid P, Thavaseelan J, Yu RJ et al (2012) Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 79(1):5\u201311","journal-title":"Urology"},{"issue":"2","key":"249_CR74","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2013.01.008","volume":"64","author":"TA McNicholas","year":"2013","unstructured":"McNicholas TA, Woo HH, Chin PT, Bolton D, Fernandez Arjona M, Sievert KD et\u00a0al (2013) Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol 64(2):292\u2013299","journal-title":"Eur. Urol."},{"issue":"1","key":"249_CR75","first-page":"7094","volume":"21","author":"N Shore","year":"2014","unstructured":"Shore N, Freedman S, Gange S, Moseley W, Heron S, Tutrone R et al (2014) Prospective multi-center study elucidating patient experience after prostatic urethral lift. Can J Urol 21(1):7094\u20137101","journal-title":"Can J Urol"},{"issue":"2","key":"249_CR76","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1743-6109.2011.02568.x","volume":"9","author":"HH Woo","year":"2012","unstructured":"Woo HH, Bolton DM, Laborde E, Jack G, Chin PT, Rashid P et\u00a0al (2012) Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J\u00a0Sex Med 9(2):568\u2013575","journal-title":"J Sex Med"},{"issue":"4","key":"249_CR77","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2014.10.031","volume":"67","author":"M Perera","year":"2015","unstructured":"Perera M, Roberts MJ, Doi SA, Bolton D (2015) Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol 67(4):704\u2013713","journal-title":"Eur. Urol."},{"issue":"1","key":"249_CR78","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/end.2014.0304","volume":"29","author":"K Faber","year":"2015","unstructured":"Faber K, de Abreu AL, Ramos P, Aljuri N, Mantri S, Gill I et al (2015) Image-guided robot-assisted prostate ablation using water jet-hydrodissection: initial study of a novel technology for benign prostatic hyperplasia. J Endourol 29(1):63\u201369","journal-title":"J Endourol"},{"issue":"6","key":"249_CR79","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/bju.13358","volume":"117","author":"P Gilling","year":"2016","unstructured":"Gilling P, Reuther R, Kahokehr A, Fraundorfer M (2016) Aquablation \u2013 image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int 117(6):923\u2013929","journal-title":"BJU Int."},{"issue":"2","key":"249_CR80","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bju.12868","volume":"115","author":"P Sturch","year":"2015","unstructured":"Sturch P, Woo HH, McNicholas T, Muir G (2015) Ejaculatory dysfunction after treatment for lower urinary tract symptoms: retrograde ejaculation or retrograde thinking? BJU Int 115(2):186\u2013187","journal-title":"BJU Int."}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-016-0249-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-016-0249-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-016-0249-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T15:50:25Z","timestamp":1568476225000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-016-0249-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,19]]},"references-count":80,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["249"],"URL":"https:\/\/doi.org\/10.1007\/s00120-016-0249-4","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,19]]}}}